Format

Send to

Choose Destination
See comment in PubMed Commons below
Ann Oncol. 2012 Aug;23(8):2103-8. doi: 10.1093/annonc/mdr580. Epub 2012 Jan 6.

Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib.

Author information

1
Caduceus Information Systems Inc., Toronto, ON, Canada. george.dranitsaris@gmail.com

Abstract

BACKGROUND:

This study describes a repeated measures prediction index to identify patients at high risk of ≥grade 2 hand-foot skin reaction (HFSR) before each week of sorafenib therapy.

METHODS:

Data from 451 patients who received a sorafenib (400 mg bid) as part of a clinical trial were reviewed (Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134). Generalized estimating equations were used to develop the final risk model. A risk-scoring algorithm (range 0-58) was then derived from the final model coefficients. External validation was then carried out on a new sample of 1145 patients who received sorafenib under an expanded access program.

RESULTS:

Pretreatment white blood cell count, female gender, good performance status, presence of lung and liver metastases and number of affected organs were predictors for ≥grade 2 HFSR. A nonlinear association between HFSR risk and treatment duration was also identified where risk was maximized at week 5 followed by a gradual decline. Before each week of therapy, patients with risk scores>40 would be considered at high risk for developing ≥grade 2 HFSR.

CONCLUSIONS:

The application and planned continued refinement of this prediction tool will be an important source of patient-specific risk information for the development of moderate to severe HFSR.

PMID:
22228446
PMCID:
PMC3403729
DOI:
10.1093/annonc/mdr580
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems Icon for PubMed Central
    Loading ...
    Support Center